Efficacy and Safety of Donidalorsen for Hereditary Angioedema.
Marc A RiedlRaffi TachdjianWilliam R LumryTimothy CraigGül KarakayaAsli GelincikMarcin StobieckiJoshua S JacobsNihal M GokmenAvner ReshefMark M GompelsMichael E ManningLaura BordoneKenneth B NewmanSabrina TreadwellSophie WangAaron YarlasDanny M Cohnnull nullPublished in: The New England journal of medicine (2024)
Donidalorsen treatment reduced the hereditary angioedema attack rate, a finding that supports potential prophylactic use for hereditary angioedema. (Funded by Ionis Pharmaceuticals; OASIS-HAE ClinicalTrials.gov number, NCT05139810.).